Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.

about

Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.

Item

http://www.wikidata.org/entity/Q55040337

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Molecular imaging with positro ...... r: a cost-effectiveness study.

@en

Molecular imaging with positron emission tomography and computed tomography

@nl

type

Item

label

Molecular imaging with positro ...... r: a cost-effectiveness study.

@en

Molecular imaging with positron emission tomography and computed tomography

@nl

prefLabel

Molecular imaging with positro ...... r: a cost-effectiveness study.

@en

Molecular imaging with positron emission tomography and computed tomography

@nl

P1476

Molecular imaging with positro ...... r: a cost-effectiveness study.

@en

P2093

David Parkin

http://www.w3.org/2001/XMLSchema#string

Karin M Vermeulen

http://www.w3.org/2001/XMLSchema#string

Marcel J W Greuter

http://www.w3.org/2001/XMLSchema#string

Talitha L Feenstra

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.

Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS).

The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients

P304

19836-19846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24869

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29731987

http://www.w3.org/2001/XMLSchema#string

P932

5929430

http://www.w3.org/2001/XMLSchema#string